

**PRIOR AUTHORIZATION PROGRAM REIMBURSEMENT REQUEST FORM**  
**For asthma therapy: Nucala (mepolizumab)**

Please fax form to:  
**1-866-840-1509**

Please note that the patient **AND** physician must complete this form. **All fields are mandatory and must be completed. Incomplete forms may result in your application being declined.** Please retain a copy of this form for your records.

**Instructions:**

- 1. PLEASE PRINT CLEARLY AND COMPLETE ALL SECTIONS.**
2. The patient/plan member must complete section A.
3. Your physician must complete section B. The cost, if any, of completing this form is at the expense of the patient/plan member.
4. Please return the form to your insurance company via Pharmacy Services at TELUS Health (a service provider of your insurance company) by fax to **1-866-840-1509**.
5. If you have any questions on the application of this program or the decision on reimbursement, or to inquire on the status of your Reimbursement Request Form, please contact your insurer.

<b>A. Information to be Completed by Patient</b>		
Employee or Insured's Name	Drug Card Number ____ - ____ - ____ - ____	
Patient's Name	Patient's Date of Birth (DD/MMM/YYYY) __ / __ / ____	Relationship to Employee/Insured <input type="checkbox"/> Employee <input type="checkbox"/> Spouse <input type="checkbox"/> Dependent
<p><b>Please allow two business days for a response once all information is received and complete.</b>  <b>Notification of the results of this request will occur Monday to Friday between 9 am and 4 pm Eastern Time.</b></p>		

Please provide contact information and indicate **ONE** method of preferred contact for notification of the results:

<input type="checkbox"/> E-mail me at:	<input type="checkbox"/> Call me (and leave a message if I'm not there) at:	<input type="checkbox"/> Fax me at:
<input type="checkbox"/> Contact my pharmacy: Pharmacy Name		Pharmacy Phone Number

I certify that the information provided by me is true, correct and complete to the best of my knowledge. I authorize my insurance company, TELUS Health (a service provider of my insurance company), their authorized representatives, agents and service providers to use and exchange this information needed for underwriting, administration and paying claims with any person or organization who has relevant information pertaining to this claim including health professionals, institutions and investigative agencies in the event of an audit. I authorize my insurance company and/or TELUS Health (a service provider of my insurance company) to contact any licensed physician, institution, pharmacy or person who has any records or knowledge of me or my health with respect to this submitted claim.

SIGNATURE OF PATIENT/PARENT/LEGAL GUARDIAN \_\_\_\_\_

Date: (DD/MMM/YYYY): \_\_ / \_\_ / \_\_\_\_

**PRIOR AUTHORIZATION PROGRAM REIMBURSEMENT REQUEST FORM**  
**For asthma therapy: Nucala (mepolizumab)**

Please fax form to:  
**1-866-840-1509**

**B. Information to be Completed by Prescribing Physician**

Drug Name	Strength	Dose
<b>Nucala (mepolizumab)</b>		

**Nucala (mepolizumab) will be eligible for reimbursement only if the patient satisfies the conditions listed below and if the patient does not qualify for coverage under any other drug plan or government mandated program.** If the patient is covered under another drug plan or government mandated program, the prior authorization program, as part of your drug benefits, may cover the portion not paid for by the primary plan. If “None of the above criteria” is indicated, the patient will not be eligible for reimbursement. **For Quebec plan members, please refer to the RAMQ exception drug criteria, if applicable.**

**Eligibility Criteria**

Please indicate if the patient satisfies the following criteria:

**Initial Criteria: Severe Eosinophilic Asthma (T990000023)** (approval period of one year):

- Patient has a confirmed diagnosis of severe eosinophilic asthma
- Nucala will be used as an add-on maintenance treatment to high-dose inhaled corticosteroids (patients ≥ 18 years of age) or medium-to-high-dose inhaled corticosteroids (patients 6-17 years of age)<sup>i</sup> and an additional asthma controller(s) (e.g., long-acting beta-agonist)
- Patient must:
  - Be ≥6 years of age;
  - Have a blood eosinophil count of ≥ 150 cells/μL (0.15 GI/L) at initiation of treatment with Nucala OR ≥ 300 cells/μL (0.3 GI/L) in the past 12 months.
  - Have a history of two or more exacerbations requiring treatment with systemic corticosteroids
  - Have persistent airflow obstruction as indicated by a pre-bronchodilator Forced Expiratory Volume in one second (FEV<sub>1</sub>) <80% predicted (in the presence of reduced FEV<sub>1</sub>/FVC defined as less than the lower limit of normal)
  - Be receiving maintenance treatment with systemic corticosteroids of at least 5.0 mg/day of prednisone or equivalent in the previous 6 months
- Physician is a respirologist or other specialist in the treatment of asthma
- Nucala will not be used as dual therapy with another monoclonal antibody for the treatment of asthma

**Renewal Criteria: Severe Eosinophilic Asthma** (approval period of one year):

Treatment with Nucala has resulted in clinical improvement as demonstrated by one or more of the following:

- Increase in percent predicted FEV<sub>1</sub> from pretreatment baseline  
OR
- Decreased use of rescue medications from pretreatment baseline  
OR
- Decreased frequency of exacerbations requiring an increase in inhaled corticosteroid dose or systemic corticosteroids use from pretreatment baseline

OR

**Initial Criteria: Eosinophilic Granulomatosis with Polyangiitis (82275008)** (approval period of one year):

- Patient has a confirmed diagnosis of eosinophilic granulomatosis with polyangiitis (also known as Churg-Strauss Syndrome)
- Patient must:
  - Be ≥18 years of age
  - Have had a 3-month trial of a glucocorticoid, unless contraindicated or clinically significant adverse events are experienced.
  - Have a history of relapsing or refractory disease.
- Prescribed by or in consultation with a/an pulmonologist, rheumatologist, immunologist, or nephrologist.

**PRIOR AUTHORIZATION PROGRAM REIMBURSEMENT REQUEST FORM**  
**For asthma therapy: Nucala (mepolizumab)**

Please fax form to:  
**1-866-840-1509**

Eligibility Criteria
<p><b>Renewal Criteria: Eosinophilic Granulomatosis with Polyangiitis</b> (approval period of one year):                      Treatment with Nucala has resulted in clinical improvement as demonstrated by:</p> <p><input type="checkbox"/> Birmingham Vasculitis Activity Score (BVAS) = 0 (no active vasculitis), AND</p> <p><input type="checkbox"/> Prednisolone or prednisone dose less than or equal to 4 mg/day</p> <p>OR</p> <p><input type="checkbox"/> None of the above applies</p> <p>Relevant additional information _____</p>

Physician Information				
Physician's Name	License Number	Telephone Number	Fax Number	
Address	City	Province	Postal Code	
Physician's Signature		Date: (DD/MMM/YYYY) ____ / ____ / ____		